Statement Of Cash Flows [Abstract]

HEMOGENYX PHARMACEUTICALS PLC - Filing #5969073

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
4,140,059 GBP
6,105,570 GBP
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
13,285 GBP
117,285 GBP
Interest received, classified as investing activities
23,164 GBP
85,344 GBP
Cash flows from (used in) investing activities
1,732 GBP
31,941 GBP
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing other equity instruments
3,712,490 GBP
5,088,076 GBP
Repayments of borrowings, classified as financing activities
635,037 GBP
638,765 GBP
Cash flows from (used in) financing activities
3,077,453 GBP
4,449,311 GBP
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
1,064,338 GBP
1,688,200 GBP
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
23,998 GBP
403,043 GBP
Cash and cash equivalents
159,265 GBP
1,247,601 GBP
2,532,758 GBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.